[en] Neurogenic primary or associated secondaries metabolize calcium through different metabolic pathways. Moreover the calcium ions in malignancies play an important role on the spread of metastasis. To assess the extent of spread of malignancy and metastasis a series of calcium-binding proteins have been identified. In addition, the assessment of integrity of staging neurogenic malignancy, and post-therapeutic viability, the calcium ion can also be targeted for diagnosis utilizing various chelating agents. Quantitatively, ultrasonography can detect a neurogenic malignant lesion in a patient earlier than CT, even when calcium ion concentration is low enough, as demonstrated in our studies in abdominal neuroblastoma. However their role to assess functional viability of malignant tumors using ultrasonography, CT and MRI are very much limited. In addition several hydroxyapatite crystal-binding radiopharmaceuticals have been used in nuclear oncology, but most of them were not lesion specific, because of their chemo adsorption by normal bone/tissue having hydroxyapatite mineral. With this aim we conducted our studies in patients with varieties of neurogenic tumors (Optic nerve tumors, Melanoma, Medullary thyroid cancer, Melanoma, Neurogennic carcinoma of urinary bladder, Carcinoid rectum etc.) with Tc-99m (V) Dimercaptosuccinic acid having special affinity for ionic calcium. The DMSA kits were prepared locally and labeled with Tecnetium-99m at pentavalent state. After the quality control each patients were injected a dose of 15-20 mCi of Tc-99m labeled DMSA.The whole body images were taken after two hrs and the images were analyzed for the accumulation of radiopharmaceutical. Our findings confirmed the accumulation of Tc-99m (V) DMSA in neurogenic malignancy sites and were comparable with the Images obtained using other modalities and histochemical findings. The scan can also be utilized for differentiating necrosis from recurrence. The Tc-99m (V) DMSA is cheaper, widely available modality, having good sensitivity and specificity for neurogenic tumors. (authors)